These findings provide new mechanistic insight into our observation of PRDX1 upregulation in BLCA and suggest that targeting PRDX1 may represent a promising therapeutic strategy by sensitizing tumor cells to ferroptosis and restoring anti-tumor immunity. Here, PRDX1 is linked to bladder transitional cell carcinoma.